Evidence map›Paper›PMID 36289712›Full record

ReviewBiomedicines2022

NF-κB Mutations in Germinal Center B-Cell Lymphomas: Relation to NF-κB Function in Normal B Cells.

Laura Pasqualucci, Ulf Klein

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. NF-kB's contribution to B cell fate decisions.Frontiers in immunology · 2023
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Laura PasqualucciInstitute for Cancer Genetics, Department of Pathology & Cell Biology, The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
Ulf KleinDivision of Haematology & Immunology, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds LS9 7TF, UK.
Columbia University · USSt James's University Hospital · GB

Funding

Role of MLL2 Gene Inactivation in B cell Non Hodgkin LymphomaR01CA172492 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PASQUALUCCI, LAURA · 2013 to 2022
$3.6M
The Role of NF-kB in B-Cell Differentiation and LymphomagenesisR01CA157660 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KLEIN, ULF · 2012 to 2016
$1.6M
Role of IRF4-NOTCH2 Interplay in B-Cell Development and MalignancyR21CA175461 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KLEIN, ULF · 2013 to 2014
$378k
Leukemia and Lymphoma Society Translational Research Project awardNCI NIH HHS R01 CA157660NCI NIH HHS R01CA157660NCI NIH HHS R01 CA172492NCI NIH HHS R01-CA172492NCI NIH HHS R21 CA175461NCI NIH HHS R21CA175461
6 · The paper itself

Abstract

Most B cell lymphomas arise from the oncogenic transformation of B cells that have undergone the germinal center (GC) reaction of the T cell-dependent immune response, where high-affinity memory B cells and plasma cells are generated. The high proliferation of GC B cells coupled with occasional errors in the DNA-modifying processes of somatic hypermutation and class switch recombination put the cell at a risk to obtain transforming genetic aberrations, which may activate proto-oncogenes or inactivate tumour suppressor genes. Several subtypes of GC lymphomas harbor genetic mutations leading to constitutive, aberrant activation of the nuclear factor-κB (NF-κB) signaling pathway. In normal B cells, NF-κB has crucial biological roles in development and physiology. GC lymphomas highjack these activities to promote tumour-cell growth and survival. It has become increasingly clear that the separate canonical and non-canonical routes of the NF-κB pathway and the five downstream NF-κB transcription factors have distinct functions in the successive stages of GC B-cell development. These findings may have direct implications for understanding how aberrant NF-κB activation promotes the genesis of various GC lymphomas corresponding to the developmentally distinct GC B-cell subsets. The knowledge arising from these studies may be explored for the development of precision medicine approaches aimed at more effective treatments of the corresponding tumours with specific NF-κB inhibitors, thus reducing systemic toxicity. We here provide an overview on the patterns of genetic NF-κB mutations encountered in the various GC lymphomas and discuss the consequences of aberrant NF-κB activation in those malignancies as related to the biology of NF-κB in their putative normal cellular counterparts.

Indexed as

B cellB-cell developmentdiffuse large B-cell lymphomagenetic aberrationgerminal centerHodgkin lymphomalymphomalymphomagenesisNF-κB signaling pathway

Identifiers

PMID36289712
PMCPMC9599362
OpenAlexW4303613773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.